ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

424
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
10 Oct 2023 17:30

HK Short Interest Weekly: Wuxi Bio, Xpeng, Mnso, Bidu, Meituan, China Mobile, Baba

We analyzed the latest HK SFC report for aggregate short position as of Sep 29th and highlight short interest changes in Wuxi Bio, Xpeng, Mnso,...

Logo
411 Views
Share
03 Oct 2023 08:00

Hong Kong Connect Flows: $7.3bn of Inflows in September

We analyzed the Hong Kong Connect Scheme for September and highlight flows for ICBC,  CCB, Meituan, Innovent Biologics, Xpeng and Petrochina.

Logo
370 Views
Share
25 Sep 2023 15:22

Global Equity Managers Trim EM Underweight, but Remain Bearish

A growing number of Global Equity long-only funds are rotating back in, or moving to an overweight stance in Emerging Markets.

Logo
357 Views
Share
11 Sep 2023 21:11

Innovent Biologics Placement - Has Ample Cash but the Discount Is Enticing

Innovent Biologics Inc (1801 HK) (IB) aims to raise around US$313m for R&D and marketing. In this note, we talk about the deal dynamics and run the...

Logo
521 Views
Share
06 Sep 2023 12:34

Hong Kong Connect Flows (August): $8.8bn Outflows

We analyzed the Hong Kong Connect Scheme for the month of August and highlight flows for Meituan, CCB, China Mobile, CNOOC, HKEX.

Logo
350 Views
Share
x